Study of malignancy grading of breastcancer based on binding of a lectin helix pomatia agglutinin (HPA)

本文应用组织化学方法研究了164例乳腺癌组织中HPA和DBA的表达及其与预后、各种临床病理因素、核异型性分级、激素受体水平和核DNA含量的关系。福尔马林固定的石蜡包埋切片进行HPA和DBA染色。仅正常乳管上皮细胞的细胞膜和乳腺癌细胞的细胞膜、胞浆或胞浆单独染色。HPA阳性率为62.2%，DBA阳性率为34.8%。在HPA结合与临床病理因素的关系方面，肿瘤直径2.1 cm及5.0 cm及5.1 cm及5.1 cm者HPA阳性率显著高于2 cm及以下者。N(+)组明显高于n(-)组。根据…分期，I期HPA阳性率明显低于I期在组织学类型上，实体管状癌和硬化癌的HPA阳性率显著高于乳头状管状癌。未观察到绝经状态与HPA结合的关系。HPA结合与核异型性程度或激素受体水平无关，但与核DNA含量显著相关。在预后方面，HPA阳性患者的累积无瘤生存率和累积生存率均低于HPA阴性患者。此外，在ER阳性、绝经后和I期患者中，HPA阳性患者的无瘤生存率均显著低于HPA阴性患者；在肿瘤直径小于或等于2 cm及绝经前患者中，HPA阳性患者的累积无瘤生存率显著低于HPA阴性患者。DBA结合率与各种临床病理因素的关系，与肿瘤大小、组织学类型、绝经状态无关，但n(+)组明显高于n(-)组。根据TNM分期，I期明显低于II、III、IV期。在预后方面，DBA阳性患者的累积无瘤生存率和累积生存率均显著低于DBA阴性患者。在非二倍体型中，DBA阳性患者的累积无瘤生存率明显低于DBA阴性患者。因此，联合评估乳腺癌组织中HPA和DBA结合与核异型性程度、核DNA含量和激素受体水平有助于分析单个病例的生物学特征，并提供重要的临床信息。较少

Binding of HPA and DBA to breast cancer tissues was studied histochemically, and their relationships with the prognosis, various clinicopathological factors, grade of nuclear atypism, hormone receptor levels, and nuclear DNA content were evaluated in 164 cases of primary breast cancer.1. Formalin-fixed, paraffin-embedded sections were stained for HPA and DBA. Only the cell membrane of the normal lactiferous duct epithelial cells and the cell membrane and the cytoplasm or the cytoplasm alone of breast cancer cells were stained. HPA was positive in 62.2%, and DBA in 34.8%.2. Concerning the relationship of HPA binding with clinicopathological factors, the HPA positivity rate was significantly higher in tumors 2.1 cm or more and 5.0 cm or less in diameter and those 5.1 or more in diameter than in those 2 cm or less in diameter. It was significantly higher in n(+) cases than in n(-) cases. According to the Tnm classification, the HPA positivity rate was significantly lower in stage I than i … More n stages II, III, or IV. Concerning the histological type, the HPA positivity rate was significantly higher in solid-tubular carcinoma and scirrhous carcinoma than in papillotubular carcinoma. No relationship was observed between the state of menopause and HPA binding.3. HPA binding was not related to the grade of nuclear atypism or hormone receptor levels, but it was significantly related to nuclear DNA content.4. As for the prognosis, the cumulative disease-free survival rate and the cumulative survival rate were both poorer in HPA-positive cases than in HPA-negative cases. In addition, they were both significantly lower in HPA-positive than HPA-negative cases among those positive for ER, those postmenopause, and those in stage I. The cumulative disease-free survival rate was significantly lower in HPA-positive than HPA-negative cases among those having tumors 2 cm or less in diameter and those premenopause.5. Concerning the relationship of DBA binding with various clinicopathological factors, it was not related with the tumor size, histological type, or menopausal state, but it was significantly higher in n(+) cases than in n(-) cases. According to the Tnm classification, it was significantly lower in stage I than in stage II, III, or IV.6. Concerning the prognosis, the cumulative disease-free survival rate and the cumulative survival rate were both significantly poorer in DBA-positive than DBA-negative cases. In addition they were both significantly poorer in DBA-positive than negative among those positive for ER and those postmenopause.In non-diploid type the cumulative disease-free survival rate was significantly lower in DBA-positive than DBA-negative patients.From these findings, simultaneous evaluation of HPA and DBA binding of breast cancer tissues with the grade of nuclear atypism, nuclear DNA content, and hormone receptor levels is considered to be useful for analysis of biological characteristics of individual cases and to provide important clinical information. Less